The median (min–max) duration of AML disease at baseline in phase 1 patients was 0.13 (0.0–0.5) months (Supplementary Table S2); 4/13 (30.8%) patients were also positive for FLT3-ITD at baseline. The gene discussed is FLT3; the disease is acute myeloid leukemia.